These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35153267)

  • 21. Amiodarone-Induced Hyponatremia Masked by Tolvaptan in a Patient with an Implantable Left Ventricular Assist Device.
    Nakamura M; Sunagawa O; Kugai T; Kinugawa K
    Int Heart J; 2017 Dec; 58(6):1004-1007. PubMed ID: 29151494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Pose-Reino A; Runkle de la Vega I; de Jong-Laird A; Kabra M; Lindner U
    Adv Ther; 2021 Feb; 38(2):1055-1067. PubMed ID: 33306187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.
    Tuli G; Tessaris D; Einaudi S; De Sanctis L; Matarazzo P
    J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):288-292. PubMed ID: 28515029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug.
    Graziani G; Cucchiari D; Aroldi A; Angelini C; Gaetani P; Selmi C
    J Neurol Neurosurg Psychiatry; 2012 May; 83(5):510-2. PubMed ID: 22323742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A case of venlafaxine-induced syndrome of inappropriate ADH secretion (SIADH) - treatment with tolvaptan].
    Meyer I; Frank D; Janssens U
    Dtsch Med Wochenschr; 2012 May; 137(21):1096-9. PubMed ID: 22588654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Syndrome of inappropriate antidiuretic hormone release as the initial presentation of adenocarcinoma of the colon.
    Jayadeep S; B N; Vidyasagar S; Varma M; Khan MF; Pai K
    J R Coll Physicians Edinb; 2020 Sep; 50(3):277-280. PubMed ID: 32936102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [SIADH and vaptans].
    Decaux G
    Ann Endocrinol (Paris); 2012 Apr; 73(2):130-4. PubMed ID: 22537510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Symptomatic therapy of SIADH in small cell lung cancer by tolvaptan].
    Schnaiter A; Hiddemann W
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2077-9. PubMed ID: 25268207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of hyponatremia: role of vaptans].
    Hensen J
    Internist (Berl); 2010 Dec; 51(12):1499-509. PubMed ID: 21104220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
    Dasta JF; Chiong JR; Christian R; Lin J
    Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
    Arima H; Goto K; Motozawa T; Mouri M; Watanabe R; Hirano T; Ishikawa SE
    Endocr J; 2021 Jan; 68(1):17-29. PubMed ID: 32863282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience.
    Park GH; Lee CM; Song JW; Jung MC; Kim JK; Song YR; Kim HJ; Kim SG
    Korean J Intern Med; 2018 May; 33(3):561-567. PubMed ID: 28286940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current options of treatment of hyponatremia].
    Tesař V
    Vnitr Lek; 2016; 62 Suppl 6():97-101. PubMed ID: 28124939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) due to bortezomib in a case of light chain multiple mieloma. Treatment with tolvaptan.
    Carreño A; Hernández B; Mayoralas Á; Calle C
    Nefrologia; 2017; 37(5):558-559. PubMed ID: 28946972
    [No Abstract]   [Full Text] [Related]  

  • 36. Tolvaptan for the management of syndrome of inappropriate antidiuretic hormone secretion: lessons learned in titration of dose.
    Torres AC; Wickham EP; Biskobing DM
    Endocr Pract; 2011; 17(4):e97-100. PubMed ID: 21613055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion.
    Perelló-Camacho E; Pomares-Gómez FJ; López-Penabad L; Mirete-López RM; Pinedo-Esteban MR; Domínguez-Escribano JR
    Sci Rep; 2022 Jun; 12(1):10266. PubMed ID: 35715573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Dos and don'ts' in the management of hyponatremia.
    Aylwin S; Burst V; Peri A; Runkle I; Thatcher N
    Curr Med Res Opin; 2015; 31(9):1755-61. PubMed ID: 26173050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolvaptan treatment of severe stroke-like symptoms and bilateral subcortical diffusion restriction due to syndrome of inappropriate secretion of ADH after polytrauma.
    Kraayvanger L; Latza J; Vockelmann C; Berlit P; Weber R
    J Neurol; 2014 Jul; 261(7):1436-8. PubMed ID: 24859331
    [No Abstract]   [Full Text] [Related]  

  • 40. [Diagnostics and new treatment methods of syndrome of inappropriate antidiuretic hormone secretion (SIADH)].
    Trolle C; Rittig S; Frøkjær J; Jørgensen JO
    Ugeskr Laeger; 2012 Apr; 174(15):1019-22. PubMed ID: 22487409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.